Please Wait.....
Report
Motion Sickness Treatment Market By Drug Class (Antihistamines, Anticholinergics, Others), By Route of Administration (Oral, Others), By Distribution Channel (Hospital Pharmacies, Drug Store and Retail Pharmacies, Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031
Market Report I 2023-03-01 I 263 Pages I Allied Market Research
The motion sickness treatment market size valued for $393.70 million in 2021 and is estimated to reach $525.03 million by 2031, exhibiting a CAGR of 2.9% from 2022 to 2031.Motion sickness, also known as travel sickness or kinetosis, is a condition characterized by a set of symptoms that occur when a person is exposed to motion or movement.It occurs when there is a discrepancy between the sensory information that the eyes, inner ear, and body provide to the brain. The brain receives conflicting informationfrom the eyes and inner ear about the movement and orientation of the body, and this can cause a variety of symptoms such as nausea, vomiting, dizziness, headaches,sweating, and fatigue. It can be caused by various forms of motion, including car rides, airplane flights, boat rides, or even virtual reality experiences.
Motionsickness is more likely to occur in people more prone to it, such as children, pregnant women, and people with a history of migraines. Treatment for motion sickness mayinclude over-the-counter and prescription medications which includes antihistamines, anticholinergics and other medications. The products are available in branded as wellas generic form and can be easily accessed through retail and other pharmacies.Major factors that drive the growth of the motion sickness treatment market include increase in incidences of motion sickness, and rise in awareness among the peopleregarding motion sickness and its treatment options.
In addition, increase in number of travelers is also a major factor contributing toward the market growth. Forinstance, the World Tourism Organization (UNWTO) stated that more than 900 million tourists travelled internationally in 2022 which was double the number recorded in2021. This shows a significant increase in the number of travelers, both domestically and internationally. In addition, an article, Motion Sickness: Manifestations andPrevention published by Defence Food Research Laboratory, Mysore stated that, about 5 to 10% of travelers are highly susceptible to motion sickness, while others aremoderately susceptible. Thus, it highlights huge incidences of motion sickness among the travelers around the globe, which furthers propels the growth of the motionsickness treatment market.
In addition, major key players are focusing on developing new drugs and APIs that are highly potent and efficient in reducing the symptoms of motion sickness. Moreover,there is an increase in outsourcing research activities by the pharmaceutical companies to private contract research organizations (CROs), which allows the company tostay competitive and flexible in a world of increasingly advanced technologies. This supports the key market players to develop novel drug and medications for motionsickness prevention and treatment, which further propels the growth of the market.
On the other hand, lack of awareness about motion sickness and its available treatment in some underdeveloped countries hinder the growth of the market. In addition, somepeople may be hesitant to use medication to treat motion sickness due to concerns about side effects or a preference for natural remedies. This is projected to limit thedemand for motion sickness medications. Moreover, the presence of alternate solutions, such as wearable, for motion sickness may indeed be a hindrance to the marketgrowth. Wearable devices, such as acupressure bands, wristbands, and headsets, have become increasingly popular in recent years as non-pharmaceutical alternatives formanaging motion sickness. These factors limit the growth of the market.
However, emerging economies of Asia-Pacific and LAMEA present lucrative opportunities for market players for investments. These regions are characterized by largepopulations with high levels of economic growth and increasing disposable incomes. As a result, there is a growing demand for healthcare services, raising awareness formotion sickness treatment medication. Moreover, governments in these regions are increasingly investing in healthcare infrastructure and expanding access to healthcareservices, which is further anticipated to augment themarket growth.
The motion sickness treatment market is segmented into drug class, route of administration, distribution channel and region. By drugs class, the market is categorizedinto antihistamines, anticholinergics and others. By route of administration, the market is bifurcated into oral, and others. By distribution channel, the market issegregated into hospital pharmacies, drug stores & retail pharmacies and online pharmacies. Region wise, the market is analyzed across North America (the U.S., Canada,and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), andLAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the motion sickness treatment market include Prestige Consumer Healthcare Inc., Baxter International Inc., Novartis AG, WellSpringPharmaceutical Corporation., Amneal Pharmaceuticals LLC., Abbott Laboratories, Sun Pharmaceutical Industries Ltd., Viatris Inc., Zydus Cadila and Teva PharmaceuticalIndustries Limited.
Key Benefits For Stakeholders
-This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the motion sickness treatment market analysis from 2021 to 2031 to identify the prevailing motion sickness treatment market opportunities.
-The market research is offered along with information related to key drivers, restraints, and opportunities.
-Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
-In-depth analysis of the motion sickness treatment market segmentation assists to determine the prevailing market opportunities.
-Major countries in each region are mapped according to their revenue contribution to the global market.
-Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
-The report includes the analysis of the regional as well as global motion sickness treatment market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Drug Class
- Antihistamines
- Anticholinergics
- Others
By Route of Administration
- Oral
- Others
By Distribution Channel
- Drug Store and Retail Pharmacies
- Online Pharmacies
- Hospital Pharmacies
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- Sun Pharmaceutical Industries Ltd.
- Viatris Inc.
- Teva Pharmaceutical Industries Limited
- Prestige Consumer Healthcare Inc.
- Baxter International Inc.
- Novartis AG
- Amneal Pharmaceuticals LLC
- Abbott Laboratories
- WellSpring Pharmaceutical Corporation
- Zydus Lifesciences Limited
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter's five forces analysis
3.3.1. Bargaining power of suppliers
3.3.2. Bargaining power of buyers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increasing incidence of motion sickness
3.4.1.2. Surge in adoption of motion sickness treatments
3.4.1.3. Surge in product approval and product launches by the key players
3.4.2. Restraints
3.4.2.1. Presence of alternate solution for motion sickness treatment
3.4.2.2. Limited awareness and knowledge about motion sickness
3.4.3. Opportunities
3.4.3.1. Growth opportunity in emerging markets
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS
4.1. Overview
4.1.1. Market size and forecast
4.2. Antihistamines
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Anticholinergics
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Others
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
CHAPTER 5: MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Oral
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Others
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
CHAPTER 6: MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital Pharmacies
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Drug Store and Retail Pharmacies
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Online Pharmacies
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: MOTION SICKNESS TREATMENT MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. Market size and forecast, by Drug Class
7.2.3. Market size and forecast, by Route of Administration
7.2.4. Market size and forecast, by Distribution Channel
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Key market trends, growth factors and opportunities
7.2.5.1.2. Market size and forecast, by Drug Class
7.2.5.1.3. Market size and forecast, by Route of Administration
7.2.5.1.4. Market size and forecast, by Distribution Channel
7.2.5.2. Canada
7.2.5.2.1. Key market trends, growth factors and opportunities
7.2.5.2.2. Market size and forecast, by Drug Class
7.2.5.2.3. Market size and forecast, by Route of Administration
7.2.5.2.4. Market size and forecast, by Distribution Channel
7.2.5.3. Mexico
7.2.5.3.1. Key market trends, growth factors and opportunities
7.2.5.3.2. Market size and forecast, by Drug Class
7.2.5.3.3. Market size and forecast, by Route of Administration
7.2.5.3.4. Market size and forecast, by Distribution Channel
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Market size and forecast, by Drug Class
7.3.3. Market size and forecast, by Route of Administration
7.3.4. Market size and forecast, by Distribution Channel
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Key market trends, growth factors and opportunities
7.3.5.1.2. Market size and forecast, by Drug Class
7.3.5.1.3. Market size and forecast, by Route of Administration
7.3.5.1.4. Market size and forecast, by Distribution Channel
7.3.5.2. France
7.3.5.2.1. Key market trends, growth factors and opportunities
7.3.5.2.2. Market size and forecast, by Drug Class
7.3.5.2.3. Market size and forecast, by Route of Administration
7.3.5.2.4. Market size and forecast, by Distribution Channel
7.3.5.3. UK
7.3.5.3.1. Key market trends, growth factors and opportunities
7.3.5.3.2. Market size and forecast, by Drug Class
7.3.5.3.3. Market size and forecast, by Route of Administration
7.3.5.3.4. Market size and forecast, by Distribution Channel
7.3.5.4. Italy
7.3.5.4.1. Key market trends, growth factors and opportunities
7.3.5.4.2. Market size and forecast, by Drug Class
7.3.5.4.3. Market size and forecast, by Route of Administration
7.3.5.4.4. Market size and forecast, by Distribution Channel
7.3.5.5. Spain
7.3.5.5.1. Key market trends, growth factors and opportunities
7.3.5.5.2. Market size and forecast, by Drug Class
7.3.5.5.3. Market size and forecast, by Route of Administration
7.3.5.5.4. Market size and forecast, by Distribution Channel
7.3.5.6. Rest of Europe
7.3.5.6.1. Key market trends, growth factors and opportunities
7.3.5.6.2. Market size and forecast, by Drug Class
7.3.5.6.3. Market size and forecast, by Route of Administration
7.3.5.6.4. Market size and forecast, by Distribution Channel
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Market size and forecast, by Drug Class
7.4.3. Market size and forecast, by Route of Administration
7.4.4. Market size and forecast, by Distribution Channel
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Key market trends, growth factors and opportunities
7.4.5.1.2. Market size and forecast, by Drug Class
7.4.5.1.3. Market size and forecast, by Route of Administration
7.4.5.1.4. Market size and forecast, by Distribution Channel
7.4.5.2. China
7.4.5.2.1. Key market trends, growth factors and opportunities
7.4.5.2.2. Market size and forecast, by Drug Class
7.4.5.2.3. Market size and forecast, by Route of Administration
7.4.5.2.4. Market size and forecast, by Distribution Channel
7.4.5.3. India
7.4.5.3.1. Key market trends, growth factors and opportunities
7.4.5.3.2. Market size and forecast, by Drug Class
7.4.5.3.3. Market size and forecast, by Route of Administration
7.4.5.3.4. Market size and forecast, by Distribution Channel
7.4.5.4. Australia
7.4.5.4.1. Key market trends, growth factors and opportunities
7.4.5.4.2. Market size and forecast, by Drug Class
7.4.5.4.3. Market size and forecast, by Route of Administration
7.4.5.4.4. Market size and forecast, by Distribution Channel
7.4.5.5. South Korea
7.4.5.5.1. Key market trends, growth factors and opportunities
7.4.5.5.2. Market size and forecast, by Drug Class
7.4.5.5.3. Market size and forecast, by Route of Administration
7.4.5.5.4. Market size and forecast, by Distribution Channel
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Key market trends, growth factors and opportunities
7.4.5.6.2. Market size and forecast, by Drug Class
7.4.5.6.3. Market size and forecast, by Route of Administration
7.4.5.6.4. Market size and forecast, by Distribution Channel
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by Drug Class
7.5.3. Market size and forecast, by Route of Administration
7.5.4. Market size and forecast, by Distribution Channel
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Key market trends, growth factors and opportunities
7.5.5.1.2. Market size and forecast, by Drug Class
7.5.5.1.3. Market size and forecast, by Route of Administration
7.5.5.1.4. Market size and forecast, by Distribution Channel
7.5.5.2. Saudi Arabia
7.5.5.2.1. Key market trends, growth factors and opportunities
7.5.5.2.2. Market size and forecast, by Drug Class
7.5.5.2.3. Market size and forecast, by Route of Administration
7.5.5.2.4. Market size and forecast, by Distribution Channel
7.5.5.3. South Africa
7.5.5.3.1. Key market trends, growth factors and opportunities
7.5.5.3.2. Market size and forecast, by Drug Class
7.5.5.3.3. Market size and forecast, by Route of Administration
7.5.5.3.4. Market size and forecast, by Distribution Channel
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Key market trends, growth factors and opportunities
7.5.5.4.2. Market size and forecast, by Drug Class
7.5.5.4.3. Market size and forecast, by Route of Administration
7.5.5.4.4. Market size and forecast, by Distribution Channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2021
CHAPTER 9: COMPANY PROFILES
9.1. Prestige Consumer Healthcare Inc.
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.2. Baxter International Inc.
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.3. Novartis AG
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.4. WellSpring Pharmaceutical Corporation
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.5. Amneal Pharmaceuticals LLC
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.6. Abbott Laboratories
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.7. Sun Pharmaceutical Industries Ltd.
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.8. Viatris Inc.
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.8.7. Key strategic moves and developments
9.9. Teva Pharmaceutical Industries Limited
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.10. Zydus Lifesciences Limited
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance
9.10.7. Key strategic moves and developments
LIST OF TABLES
TABLE 01. GLOBAL MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 02. MOTION SICKNESS TREATMENT MARKET FOR ANTIHISTAMINES, BY REGION, 2021-2031 ($MILLION)
TABLE 03. MOTION SICKNESS TREATMENT MARKET FOR ANTICHOLINERGICS, BY REGION, 2021-2031 ($MILLION)
TABLE 04. MOTION SICKNESS TREATMENT MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 05. GLOBAL MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 06. MOTION SICKNESS TREATMENT MARKET FOR ORAL, BY REGION, 2021-2031 ($MILLION)
TABLE 07. MOTION SICKNESS TREATMENT MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 08. GLOBAL MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 09. MOTION SICKNESS TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 10. MOTION SICKNESS TREATMENT MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 11. MOTION SICKNESS TREATMENT MARKET FOR ONLINE PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 12. MOTION SICKNESS TREATMENT MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 13. NORTH AMERICA MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 14. NORTH AMERICA MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 15. NORTH AMERICA MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 16. NORTH AMERICA MOTION SICKNESS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 17. U.S. MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 18. U.S. MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 19. U.S. MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 20. CANADA MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 21. CANADA MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 22. CANADA MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 23. MEXICO MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 24. MEXICO MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 25. MEXICO MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 26. EUROPE MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 27. EUROPE MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 28. EUROPE MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 29. EUROPE MOTION SICKNESS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 30. GERMANY MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 31. GERMANY MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 32. GERMANY MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 33. FRANCE MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 34. FRANCE MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 35. FRANCE MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 36. UK MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 37. UK MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 38. UK MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 39. ITALY MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 40. ITALY MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 41. ITALY MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 42. SPAIN MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 43. SPAIN MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 44. SPAIN MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 45. REST OF EUROPE MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 46. REST OF EUROPE MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 47. REST OF EUROPE MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 48. ASIA-PACIFIC MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 49. ASIA-PACIFIC MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 50. ASIA-PACIFIC MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 51. ASIA-PACIFIC MOTION SICKNESS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 52. JAPAN MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 53. JAPAN MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 54. JAPAN MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 55. CHINA MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 56. CHINA MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 57. CHINA MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 58. INDIA MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 59. INDIA MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 60. INDIA MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 61. AUSTRALIA MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 62. AUSTRALIA MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 63. AUSTRALIA MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 64. SOUTH KOREA MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 65. SOUTH KOREA MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 66. SOUTH KOREA MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 67. REST OF ASIA-PACIFIC MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 68. REST OF ASIA-PACIFIC MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 69. REST OF ASIA-PACIFIC MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 70. LAMEA MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 71. LAMEA MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 72. LAMEA MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 73. LAMEA MOTION SICKNESS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 74. BRAZIL MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 75. BRAZIL MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 76. BRAZIL MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 77. SAUDI ARABIA MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 78. SAUDI ARABIA MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 79. SAUDI ARABIA MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 80. SOUTH AFRICA MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 81. SOUTH AFRICA MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 82. SOUTH AFRICA MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 83. REST OF LAMEA MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 84. REST OF LAMEA MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 85. REST OF LAMEA MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 86. PRESTIGE CONSUMER HEALTHCARE INC.: KEY EXECUTIVES
TABLE 87. PRESTIGE CONSUMER HEALTHCARE INC.: COMPANY SNAPSHOT
TABLE 88. PRESTIGE CONSUMER HEALTHCARE INC.: PRODUCT SEGMENTS
TABLE 89. PRESTIGE CONSUMER HEALTHCARE INC.: PRODUCT PORTFOLIO
TABLE 90. BAXTER INTERNATIONAL INC.: KEY EXECUTIVES
TABLE 91. BAXTER INTERNATIONAL INC.: COMPANY SNAPSHOT
TABLE 92. BAXTER INTERNATIONAL INC.: PRODUCT SEGMENTS
TABLE 93. BAXTER INTERNATIONAL INC.: PRODUCT PORTFOLIO
TABLE 94. NOVARTIS AG: KEY EXECUTIVES
TABLE 95. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 96. NOVARTIS AG: PRODUCT SEGMENTS
TABLE 97. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 98. WELLSPRING PHARMACEUTICAL CORPORATION: KEY EXECUTIVES
TABLE 99. WELLSPRING PHARMACEUTICAL CORPORATION: COMPANY SNAPSHOT
TABLE 100. WELLSPRING PHARMACEUTICAL CORPORATION: PRODUCT SEGMENTS
TABLE 101. WELLSPRING PHARMACEUTICAL CORPORATION: PRODUCT PORTFOLIO
TABLE 102. AMNEAL PHARMACEUTICALS LLC: KEY EXECUTIVES
TABLE 103. AMNEAL PHARMACEUTICALS LLC: COMPANY SNAPSHOT
TABLE 104. AMNEAL PHARMACEUTICALS LLC: PRODUCT SEGMENTS
TABLE 105. AMNEAL PHARMACEUTICALS LLC: PRODUCT PORTFOLIO
TABLE 106. ABBOTT LABORATORIES: KEY EXECUTIVES
TABLE 107. ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 108. ABBOTT LABORATORIES: PRODUCT SEGMENTS
TABLE 109. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 110. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
TABLE 111. SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 112. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
TABLE 113. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 114. VIATRIS INC.: KEY EXECUTIVES
TABLE 115. VIATRIS INC.: COMPANY SNAPSHOT
TABLE 116. VIATRIS INC.: PRODUCT SEGMENTS
TABLE 117. VIATRIS INC.: PRODUCT PORTFOLIO
TABLE 118. VIATRIS INC.: KEY STRATERGIES
TABLE 119. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
TABLE 120. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
TABLE 121. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
TABLE 122. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
TABLE 123. ZYDUS LIFESCIENCES LIMITED: KEY EXECUTIVES
TABLE 124. ZYDUS LIFESCIENCES LIMITED: COMPANY SNAPSHOT
TABLE 125. ZYDUS LIFESCIENCES LIMITED: PRODUCT SEGMENTS
TABLE 126. ZYDUS LIFESCIENCES LIMITED: PRODUCT PORTFOLIO
TABLE 127. ZYDUS LIFESCIENCES LIMITED: KEY STRATERGIES
LIST OF FIGURES
FIGURE 01. MOTION SICKNESS TREATMENT MARKET, 2021-2031
FIGURE 02. SEGMENTATION OF MOTION SICKNESS TREATMENT MARKET, 2021-2031
FIGURE 03. TOP INVESTMENT POCKETS IN MOTION SICKNESS TREATMENT MARKET (2022-2031)
FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
FIGURE 05. LOW BARGAINING POWER OF BUYERS
FIGURE 06. LOW THREAT OF SUBSTITUTES
FIGURE 07. LOW THREAT OF NEW ENTRANTS
FIGURE 08. LOW INTENSITY OF RIVALRY
FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALMOTION SICKNESS TREATMENT MARKET
FIGURE 10. MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021(%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF MOTION SICKNESS TREATMENT MARKET FOR ANTIHISTAMINES, BY COUNTRY 2021 AND 2031(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF MOTION SICKNESS TREATMENT MARKET FOR ANTICHOLINERGICS, BY COUNTRY 2021 AND 2031(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF MOTION SICKNESS TREATMENT MARKET FOR OTHERS, BY COUNTRY 2021 AND 2031(%)
FIGURE 14. MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021(%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF MOTION SICKNESS TREATMENT MARKET FOR ORAL, BY COUNTRY 2021 AND 2031(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF MOTION SICKNESS TREATMENT MARKET FOR OTHERS, BY COUNTRY 2021 AND 2031(%)
FIGURE 17. MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF MOTION SICKNESS TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2021 AND 2031(%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF MOTION SICKNESS TREATMENT MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY COUNTRY 2021 AND 2031(%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF MOTION SICKNESS TREATMENT MARKET FOR ONLINE PHARMACIES, BY COUNTRY 2021 AND 2031(%)
FIGURE 21. MOTION SICKNESS TREATMENT MARKET BY REGION, 2021
FIGURE 22. U.S. MOTION SICKNESS TREATMENT MARKET, 2021-2031 ($MILLION)
FIGURE 23. CANADA MOTION SICKNESS TREATMENT MARKET, 2021-2031 ($MILLION)
FIGURE 24. MEXICO MOTION SICKNESS TREATMENT MARKET, 2021-2031 ($MILLION)
FIGURE 25. GERMANY MOTION SICKNESS TREATMENT MARKET, 2021-2031 ($MILLION)
FIGURE 26. FRANCE MOTION SICKNESS TREATMENT MARKET, 2021-2031 ($MILLION)
FIGURE 27. UK MOTION SICKNESS TREATMENT MARKET, 2021-2031 ($MILLION)
FIGURE 28. ITALY MOTION SICKNESS TREATMENT MARKET, 2021-2031 ($MILLION)
FIGURE 29. SPAIN MOTION SICKNESS TREATMENT MARKET, 2021-2031 ($MILLION)
FIGURE 30. REST OF EUROPE MOTION SICKNESS TREATMENT MARKET, 2021-2031 ($MILLION)
FIGURE 31. JAPAN MOTION SICKNESS TREATMENT MARKET, 2021-2031 ($MILLION)
FIGURE 32. CHINA MOTION SICKNESS TREATMENT MARKET, 2021-2031 ($MILLION)
FIGURE 33. INDIA MOTION SICKNESS TREATMENT MARKET, 2021-2031 ($MILLION)
FIGURE 34. AUSTRALIA MOTION SICKNESS TREATMENT MARKET, 2021-2031 ($MILLION)
FIGURE 35. SOUTH KOREA MOTION SICKNESS TREATMENT MARKET, 2021-2031 ($MILLION)
FIGURE 36. REST OF ASIA-PACIFIC MOTION SICKNESS TREATMENT MARKET, 2021-2031 ($MILLION)
FIGURE 37. BRAZIL MOTION SICKNESS TREATMENT MARKET, 2021-2031 ($MILLION)
FIGURE 38. SAUDI ARABIA MOTION SICKNESS TREATMENT MARKET, 2021-2031 ($MILLION)
FIGURE 39. SOUTH AFRICA MOTION SICKNESS TREATMENT MARKET, 2021-2031 ($MILLION)
FIGURE 40. REST OF LAMEA MOTION SICKNESS TREATMENT MARKET, 2021-2031 ($MILLION)
FIGURE 41. TOP WINNING STRATEGIES, BY YEAR
FIGURE 42. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 43. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 44. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 45. COMPETITIVE DASHBOARD
FIGURE 46. COMPETITIVE HEATMAP: MOTION SICKNESS TREATMENT MARKET
FIGURE 47. TOP PLAYER POSITIONING, 2021
FIGURE 48. PRESTIGE CONSUMER HEALTHCARE INC.: NET SALES, 2020-2022 ($MILLION)
FIGURE 49. PRESTIGE CONSUMER HEALTHCARE INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 50. PRESTIGE CONSUMER HEALTHCARE INC.: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 51. BAXTER INTERNATIONAL INC.: NET SALES, 2020-2022 ($MILLION)
FIGURE 52. BAXTER INTERNATIONAL INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 53. BAXTER INTERNATIONAL INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 54. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
FIGURE 55. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 56. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 57. AMNEAL PHARMACEUTICALS LLC: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 58. AMNEAL PHARMACEUTICALS LLC: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 59. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)
FIGURE 60. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 61. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 62. SUN PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2019-2021 ($MILLION)
FIGURE 63. SUN PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 64. VIATRIS INC.: NET SALES, 2020-2022 ($MILLION)
FIGURE 65. VIATRIS INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 66. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 67. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 68. ZYDUS LIFESCIENCES LIMITED: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 69. ZYDUS LIFESCIENCES LIMITED: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 70. ZYDUS LIFESCIENCES LIMITED: REVENUE SHARE BY REGION, 2022 (%)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security